UroToday

PAM50 Intrinsic Subtyping and Salvage Therapy Decisions After Prostatectomy - Jonathan Tward

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday

Considerations for Managing Patients as They Progress to Castration-Resistant Prostate Cancer - Tian Zhang

Tian Zhang outlines management strategies for patients progressing from metastatic hormone-sensitive to castration-resistant prostate cancer with upfront expectation-setting discussions. Dr. Zhang ...
UroToday

Cohort P Data from the BOND-003 Study in BCG-Unresponsive Papillary Bladder Cancer - Mark Tyson

Mark Tyson speaks with Zachary Klaassen about Cohort P results from the BOND-003 trial evaluating cretostimogene grenadenorepvec in BCG-unresponsive papillary-only non-muscle-invasive bladder cancer.
UroToday

CORE-008 Cohort A First Results on Cretostimogene Grenadenorepvec for BCG-Naive Bladder Cancer - Shane Pearce

Shane Pearce presents CORE-008 Cohort A results with Sam Chang. The phase 2 trial enrolled BCG-naive high-risk NMIBC patients with CIS plus or minus papillary disease. Cretostimogene achieved 83.7% ...
UroToday

Correlation Between Genomic Classifier Scores and Upfront Treatment Selection in Localized Prostate Cancer: A Real-World U.S. Population-Based Cohort Study - Michael Leapman

Michael Leapman presents a population-level analysis linking SEER registry with Decipher® genomic classifier data in low and intermediate-risk prostate cancer patients. Higher Decipher® scores were ...
UroToday

Integrating Genomic Prognostic and Hallmark Signatures to Predict Outcomes in Active Surveillance - Kevin Shee

Kevin Shee analyzes Decipher® GRID whole-transcriptome data in 500 active surveillance patients from UCSF. Cox proportional regression identified Long and Yu signatures predicting upgrade risk beyond ...
UroToday

ASCO GU 2026: OPTIMAS: A Phase II Randomized, Decentralized, De-Escalation Trial in Patients with mHSPC Achieving Optimal PSA Response

The 2026 ASCO GU Annual Symposium was host to a trials-in-progress prostate cancer poster session. Dr. Umang Swami presented ...
UroToday

ASCO GU 2026: Discussant: The Era of ADCs for Urothelial Carcinoma Continues

The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...
UroToday

ASCO GU 2026: Discussant: Prevention to Progression – Targeting Foundational Biology in RCC

The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, discussing three abstracts, “Belzutifan + lenvatinib versus cabozantinib for ...
UroToday

ASCO GU 2026: A Phase II Trial of Cabozantinib in Relapsed Refractory Germ Cell Tumors

The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...
UroToday

ASCO GU 2026: REJOICE-PanTumor01: A Phase 2 Signal-Seeking Study of Raludotatug Deruxtecan in Patients with Advanced or Metastatic Gynecologic or Genitourinary Tumors

(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...
UroToday

Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026

These data represent the first published dosimetry data for our investigational formulation of Lu-177 zadavotide guraxetan, with projected mean cumulative renal doses remaining low for a six-cycle ...